Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HER2 status: a statistician's view.

P Valagussa1

  • 1Operations Office, Scientific Direction, Istituto Nazionale Tumori, Milan, Italy. valagussa@istitutotumori.mi.it

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|August 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

The influential and inspirational Gianni Bonadonna's life commitment to evidence-based cancer medicine.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Management of breast cancer after Hodgkin's lymphoma and paediatric cancer.

European journal of cancer (Oxford, England : 1990)·2015
Same author

Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.

Bone marrow transplantation·2014
Same author

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2011

HER2-positive status in breast cancer may indicate a poorer outcome and resistance to hormonal therapy. However, its predictive value remains unproven due to study limitations, requiring further research.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The human epidermal growth factor receptor-2 (HER2) is a key factor in breast cancer.
  • Its role as a prognostic and predictive factor is under investigation.
  • Retrospective studies have yielded results with potential bias and limited statistical significance.

Purpose of the Study:

  • To evaluate the prognostic and predictive value of HER2 status in breast cancer.
  • To analyze the association between HER2 status and patient outcomes.
  • To assess the correlation of HER2 status with response to different therapies.

Main Methods:

  • Review of existing retrospective subset analyses on HER2 status in breast cancer.
  • Analysis of studies investigating HER2 status as a predictor of patient outcome.

Related Experiment Videos

  • Examination of research on HER2 status in relation to hormonal therapy, CMF, and anthracycline-based treatments.

    • Main Results:

    • A HER2-positive status is generally associated with a poorer patient outcome, though findings are contradictory.
    • HER2-positive status may predict resistance to hormonal therapy.
    • Evidence suggests resistance to CMF chemotherapy but chemosensitivity to anthracyclines in HER2-positive breast cancer, with significant discrepancies across studies.

    Conclusions:

    • The predictive value of HER2 status in breast cancer is currently unproven due to inconsistencies in study findings.
    • Large, prospective, and well-reported studies are necessary to establish the statistical clarity of HER2's prognostic and predictive role.
    • Therapeutic decisions should not solely rely on HER2 status at this time.